Quarterly ResultApr 28, 2026, 06:27 AM
NVS Q1 Net Sales $13.1B, -5% cc; Net Income $3.2B, -13% cc; EPS $1.65
AI Summary
Novartis AG reported a decline in its first-quarter 2026 financial results, with net sales decreasing 5% at constant currencies to $13.1 billion and net income falling 13% cc to $3.2 billion. Basic EPS also saw a drop of 11% cc to $1.65. The company completed the acquisition of Avidity Biosciences, Inc. for $12.0 billion, which significantly increased its financial debt and net debt position. While some key products like Entresto faced strong generic competition, innovative medicines such as Kisqali, Pluvicto, Kesimpta, and Scemblix demonstrated robust growth.
Key Highlights
- NVS Q1 2026 net sales were $13.1 billion, a decrease of 5% at constant currencies (cc) and 1% in USD.
- Net income for Q1 2026 was $3.2 billion, down 13% cc and 13% in USD.
- Basic earnings per share (EPS) was $1.65, a decrease of 11% cc and 10% in USD.
- Operating income declined by 11% cc to $4.2 billion, with a margin of 32.3% of net sales.
- Net cash flows from operating activities were $3.7 billion, up 1% from the prior-year quarter.
- Acquired Avidity Biosciences, Inc. for $12.0 billion, leading to a significant increase in financial debt.
- Entresto sales declined 46% cc to $1.3 billion due to generic competition in the US.
- Kisqali sales grew 55% cc to $1.5 billion, and Pluvicto sales increased 70% cc to $642 million.